Partners Seek to Develop New Imagining Agents for Cardiovascular Disease Diagnosis

Partners in a recently signed research agreement will be developing new imaging agents for the noninvasive measurement of blood flow in the heart for the diagnosis of cardiovascular diseases–a sector worth of some two billion USD annually.

Hadasit (Jerusalem, Israel), the technology transfer company of the Hadassah Medical Organization (Jerusalem, Israel) announced the initiation of a three-year license and cooperation agreement with Synektik SA (Warsaw, Poland) to develop new imagining agents for use in PET/CT scans, which will enable the quantitative measurement of blood flow to the heart. The potential agents are expected to enable the clinician to determine the extent of damage resulting from a heart attack, and predict the degree of recovery after the heart attack or bypass surgery.

Research will be conducted at the Hadassah Medical Organization in Jerusalem in cooperation with Synektik's new research and development facility in Warsaw. Development funding of four million USD will be provided by Synektik, which will receive a worldwide license for any newly developed imaging agent and will spearhead further development, clinical trials registration, and commercialization.

Dr. Eyal Mishani, director of the cyclotron and radiochemistry unit of the Hadassah Medical Organization, said, "The funding would facilitate pre-clinical research and development stages and preparation for clinical trials which will be performed jointly with Synektik."

Related Links:
Hadasit
Hadassah Medical Organization
Synektik SA